In fiscal year 2023, EuBiologics (206650) reported revenue of 69.4 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2023 | 69.4 billion KRW | 7.7 billion KRW | -15.4 billion KRW | [source] |
| 2022 | 55.5 billion KRW | -3.8 billion KRW | -3.4 billion KRW | [source] |
| 2021 | 39.4 billion KRW | -7.2 billion KRW | -28.0 billion KRW | [source] |
| 2020 | 28.5 billion KRW | -6.0 billion KRW | -60.1 billion KRW | — |
| 2019 | 33.1 billion KRW | 9.8 billion KRW | -882 million KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2023 | 151.9 billion KRW | 45.8 billion KRW | 106.1 billion KRW | [source] |
| 2022 | 160.5 billion KRW | 41.9 billion KRW | 118.6 billion KRW | [source] |
| 2021 | 148.8 billion KRW | 33.3 billion KRW | 115.5 billion KRW | [source] |
| 2020 | — | — | — | — |
| 2019 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.